Immunotherapy Resistance - Metastatic Breast Cancer Trial Talk

From the Experts

Researchers have made tremendous progress on cancer immunotherapy in the last decade. Immune checkpoint inhibitor drugs, adoptive cell therapies, and tumor vaccines are now used in various cancer clinics as alternative treatment options. For metastatic breast cancer, the FDA approved the immunotherapies Tecentriq® (atezolizumab) in 2019, and Keytruda® (pembrolizumab) in 2020, to treat some metastatic triple-negative breast cancers.

However, the outcomes of using cancer immunotherapy vary among patients. Some patients’ cancers do not respond to immunotherapies at all, while other patients’ tumors may initially respond to immunotherapies but then regrow after a while. This might be caused by immunotherapy resistance. Researchers are studying what causes immunotherapy resistance and how to overcome it.

Watch the video and read the articles below to learn more about immunotherapy resistance, and to find metastatic breast cancer clinical trials studying immunotherapy.

What is immunotherapy Resistance?
Immunotherapy Clinical Trials



for past articles or specific information.